government agencies

First Opinion By David Michaels

OSHA’s ‘absurd reinterpretation’ of a regulation regarding workers and Covid-19

Pharmalot By Ed Silverman

NIH fails to disclose enough details about drug licensing, watchdog report finds

Health By Helen Branswell

Pfizer, BioNTech submit formal application to FDA to authorize Covid-19 vaccine

Pharmalot By Ed Silverman

FDA vows to disclose data used to support emergency drug authorizations

Pharmalot By Ed Silverman

A lucrative Regeneron contract with the federal government lacks the usual taxpayer protections

By Damian Garde, Meg Tirrell, and Adam Feuerstein

Listen: Bracing for a pandemic winter, Biogen’s fortune at the FDA, and remembering a remarkable 12-year-old

Pharmalot By Ed Silverman

Critics say new NIH policy on scientific data sharing falls short

Pharmalot By Ed Silverman

Gilead faces pressure to relinquish valuable FDA voucher awarded with remdesivir approval

Pharmalot By Ed Silverman

Novartis move to defuse controversy over U.S. drug discount program is rebuffed

Politics By Lev Facher

Trump threatens to fire Fauci ‘after the election’

A STAT Investigation By Kathleen McLaughlin

HHS relaxed oversight of problematic Covid-19 tests despite being told of accuracy concerns

Politics By Lev Facher

Trump administration finalizes rule forcing insurers to disclose negotiated prices, including for drugs

Pharmalot By Ed Silverman

Public health experts push vaccine makers, HHS to release Covid-19 trial protocols

D.C. Diagnosis By Nicholas Florko

Will this be the most-watched FDA meeting ever?

Pharmalot By Ed Silverman

A defiant AMAG wants an FDA hearing rather than withdraw its premature birth drug

Health By Helen Branswell

First Ebola therapy approved by the FDA

Pharmalot By Ed Silverman

When off-label may mean off-target: How would doctors and insurers navigate demand for a new, narrow Alzheimer’s drug?

Health By Priyanka Runwal

As wildfires ravage the West, contaminated water raises health concerns

Politics By Nicholas Florko

FDA formally blasts a mask decontamination device maker once touted by Trump

Pharmalot By Ed Silverman

Appeals court hands FTC a setback that invalidates its ability to claw back millions from AbbVie

Health Tech By Rebecca Robbins, Erin Brodwin, and Casey Ross

The health tech tracker for the fourth quarter: 14 pivotal industry events to watch

Pharmalot By Ed Silverman

For two decades, the FDA approval process for opioids had numerous shortcomings, study finds

First Opinion By Liam Bendicksen, Joshua M. Sharfstein, and Aaron S. Kesselheim

Increase transparency at the FDA: We need sunlight to fight the pandemic

Pharma By Ed Silverman

An FDA safety program is failing to stem the opioid crisis — and manufacturers are mostly to blame

Special Report By Nicholas Florko

The 8 most important leaders of Operation Warp Speed